TrialPath
Heart failure · Phoenix

Heart failure clinical trials in Phoenix

20 recruiting heart failure studies within range of Phoenix. Click any trial for full eligibility criteria and contact info.

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

NCT06777368 · Aortic Stenosis
Recruiting

The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).

Phase
TypeObservational
Age18 Years – 105 Years
WhereBirmingham, Alabama, United States + 70 more
SponsorMedtronic Cardiovascular
Tap for details
Apply

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

Recruiting

Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). This study focuses on Cpc-PH that is caused by heart failure with preserved ejection fraction (HFpEF). Researchers want to know if the study treatment, sotatercept, can treat people with Cpc-PH caused by HFpEF. This is an extension study, which means people who took part in a certain study on sotatercept for Cpc-PH (called a parent study) may be able to join this study. In this extension study, people will take sotatercept and researchers will follow their health for a longer time. The main goal of this extension study is to learn about the long-term safety of sotatercept and if people tolerate it over a longer period of time.

PhasePhase 2
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 56 more
SponsorMerck Sharp & Dohme LLC
Tap for details
Apply

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Recruiting

The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.

PhaseNA
TypeInterventional
Age40 Years
WhereBirmingham, Alabama, United States + 19 more
SponsorAxon Therapies, Inc.
Tap for details
Apply

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

NCT06526195 · Heart Failure, Heart Diseases, Cardiovascular Diseases
Recruiting

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

PhaseNA
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 62 more
SponsorAbbott Medical Devices
Tap for details
Apply

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404 · Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children
Recruiting

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

Phase
TypeObservational
Age0 Years – 20 Years
WherePhoenix, Arizona, United States + 50 more
SponsorDuke University
Tap for details
Apply

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

NCT07207811 · Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Recruiting

This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.

PhasePhase 3
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 289 more
SponsorNovo Nordisk A/S
Tap for details
Apply

Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

NCT05677100 · Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome
Recruiting

Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.

PhaseNA
TypeInterventional
Age21 Years
WherePhoenix, Arizona, United States + 47 more
SponsorProcyrion
Tap for details
Apply

Assessment of CCM in HF With Higher Ejection Fraction

Recruiting

The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

PhaseNA
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 104 more
SponsorImpulse Dynamics
Tap for details
Apply

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297 · Neutropenia
Recruiting

The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.

PhasePhase 3
TypeInterventional
Age12 Years
WherePhoenix, Arizona, United States + 111 more
SponsorX4 Pharmaceuticals
Tap for details
Apply

TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)

NCT06137807 · Tricuspid Regurgitation, Tricuspid Valve Disease
Recruiting

The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system is a single use, sterile device compatible with all the valve sizes. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system.

PhaseNA
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 35 more
SponsorP+F Products + Features USA Inc.
Tap for details
Apply

Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment

NCT07403669 · Acute MI, Heart Failure, Diabetes Mellitus
Recruiting

The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.

PhaseNA
TypeInterventional
Age18 Years
WhereChandler, Arizona, United States + 4 more
SponsorAventyn, Inc.
Tap for details
Apply

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Recruiting

This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.

PhasePhase 3
TypeInterventional
Age18 Years – 130 Years
WhereAlexander City, Alabama, United States + 844 more
SponsorAstraZeneca
Tap for details
Apply

His-Bundle Corrective Pacing in Heart Failure

NCT05265520 · Right Bundle-Branch Block, Heart Failure, His-bundle Pacing
Recruiting

The investigators aim to prospectively evaluate the efficacy and mechanism of benefit of His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle branch block (RBBB).

PhaseNA
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 13 more
SponsorUniversity of Rochester
Tap for details
Apply

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961 · Atherosclerotic Cardiovascular Disease in Patients With ESKD
Recruiting

This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.

PhasePhase 2 / Phase 3
TypeInterventional
Age18 Years
WhereDecatur, Alabama, United States + 541 more
SponsorCSL Behring
Tap for details
Apply

Left vs Left Randomized Clinical Trial

Recruiting

The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications and re-interventions (e.g., lead dislodgement, infection) relative to standard of care biventricular pacing in patients with heart failure due to left ventricular systolic dysfunction (LVEF≤50%) and with either a wide QRS (≥130 ms) or with/anticipated \>40% pacing who are already receiving current standard heart failure pharmacological therapy.

PhaseNA
TypeInterventional
Age18 Years
WhereGilbert, Arizona, United States + 70 more
SponsorBaylor College of Medicine
Tap for details
Apply

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

Recruiting

TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).

PhasePhase 2
TypeInterventional
Age18 Years – 83 Years
WherePhoenix, Arizona, United States + 85 more
SponsorTectonic Therapeutic
Tap for details
Apply

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Recruiting

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.

Phase
TypeObservational
AgeAny
WhereBirmingham, Alabama, United States + 78 more
SponsorChildren's Oncology Group
Tap for details

CCM OPEN HF Registry

NCT07112924 · Heart Failure
Recruiting

The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.

Phase
TypeObservational
Age18 Years
WhereMesa, Arizona, United States + 27 more
SponsorImpulse Dynamics
Tap for details
Apply

BiVACOR® Total Artificial Heart Early Feasibility Study

NCT06174103 · Heart Failure, Biventricular Failure
Recruiting

The purpose of this study is to assess the feasibility of using the BiVACOR Total Artificial Heart (TAH) System to support adult patients with severe biventricular heart failure, or univentricular heart failure in which left ventricular assist device (LVAD) support is not recommended, who require mechanical circulatory support to sustain life. The BiVACOR TAH System is intended for use as a bridge to transplant (BTT). Feasibility will be assessed by evaluating safety and performance of the BiVACOR TAH System in study subjects.

PhaseNA
TypeInterventional
Age18 Years – 70 Years
WherePhoenix, Arizona, United States + 3 more
SponsorBiVACOR Inc.
Tap for details
Apply

ELEVATE-HFpEF Clinical Study

Recruiting

ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).

PhaseNA
TypeInterventional
Age40 Years
WherePhoenix, Arizona, United States + 43 more
SponsorMedtronic Cardiac Rhythm and Heart Failure
Tap for details
Apply